Ion Channel Safety Issues in Drug Development

Voltage-Gated Ion Channels as Drug Targets

Volumn 29, Issue , 2006, Pages 444-465

  Lagrutta, Armando A ^a   Salata, Joseph J ^a  

^a NONE

Author keywords

Genetic and acquired channelopathies; Ion channel safety issues in drug development; Regulatory industry relationship (ICH); Safety issues specific to the hERG channel; Safety pharmacology

Indexed keywords

CHANNELOPATHIES; DRUG DEVELOPMENT; INDUSTRY RELATIONSHIP; ION CHANNEL; SAFETY ISSUES; SAFETY PHARMACOLOGY;

ACCIDENT PREVENTION;

EID: 85018209751     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608141.ch8c     Document Type: Chapter

References (76)

1. http://www.ich.org and related links.
2. M.M. Dotzel, Federal Register 66, 36791, 2001. Docket 00D-1407. Full text at http://www.fda.gov/cder/guidance/4461fnl.htm.
3. http://www.safetypharmacology.org.
4. L.B. Kinter, J.P. Valentin. Safety pharmacology and risk assessment. Fundament. Clin. Pharmacol. (2002) 16, 175-182.
5. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products, London. Human Medicines Evaluation Unit (1997). Full text at http://www.emea.eu.int.
6. P.K. Honig, D.C. Wortham, K. Zamani, D. P Connor, J.C. Mulin, L.R. Cantilena. Terfenadine-ketoconazole interaction. J. Am. Med. Assoc. (1993) 269, 1513-1518.
7. V. R. Vorperian, Z. Zhou, S. Mohammad, T.J. Hoon, C. Studenik, C.T. January. Torsade de Pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J. Am. Coll. Cadiol (1996) 28, 1556-1561.
8. Z. Zhou, V.R. Vorperian, Q. Gong, S. Zhang, C.T. January. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophys. (1999) 10, 836-843.
9. 1 receptor blocker cetirizine compared to other second-generation anti histamines. Mol Pharmacol. (1998) 54, 113-121.
10. J.J. Salata, N.K. Jurkiewicz, A.A. Wallace, R.F. Stupienski, P.J. Guinoso, J.J. Lynch Jr. Cardiac electrophysiological actions of the histamine H1 receptor antagonists astemizole and terfenadine compared to chlorpheniramine and pyrilamine. Circ. Res. (1995) 76, 110-119.
11. M.-Q. Zhang. Chemistry underlying the cardiotoxicity of antihistamines. Curr. Med. Chem. (1997) 4, 187-200.
12. R.L. Woosley. Cardiac actions of antihistamines. Annu. Rev. Pharmacol. Toxicol. (1996) 36, 233-252.
13. C. Pratt, A.M. Brown, D. Rampe. Cardiovascular safety of fexofenadine HCl. Clin. Exp. Allergy (1999) 29, 212-216.
14. D.K. Agrawal. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Exp. Opin. Invest. Drugs (2001) 10, 547-560.
15. B.A. Lipsky, C.A. Baker. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infectious Diseases (1999) 28, 352-364.
16. + channel HERG. Mol. Pharmacol. (2001) 59, 122-126.
17. M.I. Andersson, A.P. MacGowan. Development of the quinolones. J. Antimicrob. Chemother. (2003) 51, Suppl. S1, 1-11.
18. D.M. Taylor. Antipsychotics and QT prolongation. Acta Psychiatr. Scand. (2003) 107, 85-95.
19. S. Kongsamut, J. Kang, X.-L. Chen, J. Roehr, D. Rampe. A comparison of the receptor binding and hERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. (2002) 450, 37-41.
20. K. Titier, M. Canal, E. Deridet, A. Abouelfath, S. Gromb, M. Molimard, N. Moore. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol. Appl. Pharmacol. (2004) 199, 52-60.
21. W. Crumb, I. Cavero. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharmaceutical Science and Technology Today (1999) 2, 270-280.
22. D. Rampe, M.-L. Roy, A. Dennis, A.M. Brown. A mechanism for the proar-rhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. (1997) 417, 28-32.
23. L. Carlsson, G.J. Amos, B. Andersson, L. Drews, G. Duker, G. Wadstedt. Electro-physiological characterization of the pro-kinetic agents cisapride and mosapride in vivo and in vitro: implications for proar-rhythmic potential? J. Pharmacol. Exp. Therap. (1997) 282, 220-227.
24. + channel. J. Pharmacol. Exp. Therap. (2001) 299, 1007-1012.
25. M. Corsetti, J. Tack. Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome. Exp. Opin. Pharmac-other. (2002) 3, 1211-1218.
26. W.A. Volberg, B.J. Koci, W. Su, J. Lin, J. Zhou. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. (2002) 302, 320-327.
27. R. Dumaine, M.-L. Roy, A.M. Brown. Blockade of HERG and Kv1.5 by ketoconazole. J. Pharmacol. Exp. Therap. (1998) 286, 727-735.
28. C.-E. Chiang, H.-N. Luk, T.-M. Wang, P.Y.-A. Ding. Prolongation of cardiac repolarization by arsenic trioxide. Blood (2002) 100, 2249-2252.
29. E. Ficker, Y.A. Kuryshev, A.T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B.A. Wible, A.M. Brown. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. (2004) 66, 33-44.
30. E. Ficker, A.T. Dennis, L. Wang, A.M. Brown. Role of the cytosolic chaperones Hsp70 and Hsp90 in the maturation of the cardiac potassium channel hERG. Circ. Res. (2003) 92, E87-E100.
31. E. Ficker, C.A. Obejero-Paz, S. Zhao, A.M. Brown. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go related gene (HERG) mutations. J. Biol. Chem. (2002) 277, 4989-4998.
32. Q. Gong, C.L. Anderson, C.T. January, Z. Zhou. Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. Am. J. Physiol. Heart Circ. Physiol. (2004) 287, H652-658.
33. A.M. Brown. Drugs, hERG and sudden death. Cell Calcium (2004) 35, 543-547.
34. S. Zhang, Z. Zhou, Q. Gong, J.C. Makielski, C.T. January. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res. (1999) 84, 989-998.
35. K.H. Yuill, J.J. Borg, J.M. Ridley, J.T Milnes, H.J. Witchel, A.A. Paul, R. Z. Kozlowski, J.C. Hancox. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene - without QT interval prolongation. Biochem. Biophys. Res. Commun. (2004) 318, 556-561.
36. + channel. A model for bad behavior. J. Med. Chem. (2003) 46, 2017-2022.
37. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, M.C. Sanguinetti. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. (2000) 97, 12 329-12 333.
38. J.M. Ridley, J.T. Milnes, H.J. Witchel, J.C. Hancox. High affinity HERG channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. (2004) 325, 883-891.
39. W. Bains, A. Basman, C. White. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. (2004) 86, 205-233.
40. A.M. Aronov, B.B. Goldman. A model for identifying HERG K channel blockers. Bioorg. Med. Chem. (2004) 12, 2307-2315.
41. R.A. Pearlstein, R.J. Vaz, J. Kang, X.-L. Chen, M. Preobrazhenskaya, A.E. Shchekotikhin, A.M. Korolev, L.N. Lysenkova, O.V Miroshnikova, J. Hendrix, D. Rampe. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. (2003) 13, 1829-1835.
42. E.M.C. Jones, E.C. Roti Roti, J. Wang, S.A. Delfosse, G.A. Robertson. Cardiac ¡Kr channels minimally comprise hERG 1a and 1b subunits. J. Biol. Chem. (2004) 279, 44690-44694.
43. + channel gating: a mechanism for proarrhythmia in long QT syndrome type 6.
44. T.G. Hammond, L. Carlsson, A.S. Davis, WG. Lynch, I. MacKenzie, WS. Redfern, A.T. Sullivan, A.J. Camm. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc. Res. (2001) 49, 741-750.
45. L.B. Kinter, P.K.S. Siegl, A.S. Bass. New preclinical guidelines on drug effects on ventricular repolarizaton: Safety pharmacology comes of age. J. Pharmacol. Toxicol. Method (2004) 49, 153-158.
46. WS. Redfern, L. Carlsson, A.S. Davis, WG. Lynch, I. MacKenzie, S. Palethorpe, P.K.S. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, T.G. Hammond. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58, 32-45.
47. F. De Ponti, E. Poluzzi, N. Montanaro. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. (2000) 56, 1-18.
48. B. Fermini, A. Fossa. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev.: Drug Discov. (2003) 2, 439-447.
49. R. Fenichel, M. Malik, C. Antzelevitch, M. Sanguinetti, D.M. Roden, S.G. Priori, J.N. Ruskin, R.J. Lipicky, L.R. Cantilena. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. (2004) 15, 475-495.
50. A.A. Fossa, M.J. DePasquale, D.L. Raunig, M.J. Avery, D.J. Leishman. The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J. Pharmacol. Exp. Therap. (2002) 202, 828-833.
51. S. Spence, K. Soper, C. Hoe, J. Coleman. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxicol. Sci. (1998) 45, 247-258.
52. H. Miyazaki, M. Tagawa. Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. Exp. Anim. (2002) 51, 465-475.
53. A.A. Fossa, T Wisialowski, A. Magnano, E. Wolfgang, R. Winslow, W. Gorczyca, K. Crimin, D.L. Raunig. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J. Pharmacol. Exp. Therap. (2005) 312, 1-11.
54. G.A. Gintant, J.T. Limberis, J.S. McDermott, C.D. Wegner, B.F. Cox. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. (2001) 37, 607-618.
55. D.M. Roden. Drug-induced prolongation of the QT interval. N. England J Med (2004) 350, 1013-1022.
56. D.M. Roden. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin. Electrophysiol. (1998) 21, 1029-1034.
57. R.L. Martin, J.S. McDermott, H.J. Salmen, J. Palmatier, B.F. Cox, G.A. Gintant. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. (2004) 43, 369-379.
58. L. Carlsson, O. Almgren, G. Duker. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. (1990) 16, 276-285.
59. L.M. Hondeghem. Computer aided development of antiarrhythmic agents with class IIIa properties. J. Cardiovasc. Electrophysiol. (1994) 5, 711-721.
60. L.M. Hondeghem, L. Carlsson, G. Duker. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 103, 2004-2013.
61. L.M. Hondeghem, P. Hoffman. Blinded test in isolated female rabbit heart reliably identifies action potential duration during prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol. (2003) 41, 14-24.
62. L. Belardinelli, C. Antzelevitch, M.A. Vos. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol. Sci. (2003) 24, 619-625.
63. J.M. Di Diego, L. Belardinelli, C. Antzelevitch. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 108, 1027-1033.
64. N. Watanabe, Y. Kobayashi, K. Tanno, F. Miyoshi, T. Asano, M. Kawamura, Y. Mikami, T. Adachi, S. Ryu, A. Miyata, T. Katagiri. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J. Electrocard. (2004) 37, 191-200.
65. T. Fossa, E. Wisialowski, E. Wolfgang, M. Wang, D. Avery, B. Raunig, B. Fermini. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur. J. Pharmacol. (2004) 486, 209-221.
66. R.R. Shah. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J. Electrocard. (2005) 38, 10-18.
67. S. Nattel, B.N. Singh. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am.J. Cardiol. (1999) 84, 11R-19R.
68. Ks: potential for antiarrhythmic therapy. Curr. Med. Chem. (2004) 11, 29-44.
69. S.A. Doggrell, J.C. Hancox. Dronedarone: an amiodarone analogue. Exp. Opin. Investig. Drugs (2004) 13, 415-426.
70. C. Wright, A. Hawkes, J. Angus. Postural hypotension following N-type Ca + channel blockade is amplified in experimental hypertension. J. Hypertension (2000) 18, 65-73.
71. K.K. Jain. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Exp. Opin. Investig. Drugs (2000) 9, 2403-2410.
72. E. Teodori, E. Baldi, S. Dei, F. Gualtieri, M.N. Romanelli, S. Scapecchi, C. Belluci, C. Ghelardini, R. Matucci. Design, synthesis, and preliminary pharmacological evaluation of 4-aminopyridine derivatives as N-type calcium channel blockers active on pain and neuropathic pain. J. Med. Chem. (2004) 47, 6070-6081.
73. B. Priest, M.L. Garcia, R.E. Middleton, R.M. Brochu, S. Clark, G. Dai, I.E. Dick, J.P. Felix, C.J. Liu, B.S. Reiseter, W. A. Schmalhofer, P. P. Shao, Y.S. Tang, M. Z. Chou, M.G. Kohler, M.M. Smith, VA. Warren, B.S. Williams, C.J. Cohen, WJ. Martin, P.T. Meinke, W.H. Parsons, K.A. Wafford, G. J. Kaczorowski. A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model. Biochemistry (2004) 43, 9866-9876.
74. J.P. Felix, R.M. Bugianesi, WA. Schmalhofer, R. Borris, M.A. Goetz, O.D. Hensens, J. Bao, F. Kayser, W.H. Parsons, K. Rupprecht, M.L. Garcia, G. J. Kaczorowski, R.S. Slaughter. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry (1999) 38, 4922-4930.
75. WA. Schmalhofer, J. Bao, O.B. McManus, B. Green, M. Matyskiela, D. Wunderler, R.M. Bugianesi, J.P. Felix, M. Hanner, A.R. Linde-Arias, C.G. Ponte, L. Velasco, G. Koo, M.J. Staruch, S. Miao, W.H. Parson, K. Rupprecth, R.S. Slaughter, G.J. Kaczorowski, M.L. Garcia. Biochemistry (2002) 41, 7781-7794.
76. H. Wulff, C. Beeton, K.G. Chandy. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Dev. (2003) 6, 640-647.